CSIMarket Company Name, Ticker, Industry, else..
 
Omega Therapeutics Inc   (NASDAQ: OMGA)
 
Price: $0.1426 $0.00 0.000%
Day's High: 0.00 Week Perf: -7.4 %
Day's Low: $ 0.00 30 Day Perf: -67.83 %
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.14
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 8
 Shares Outstanding (Millions) 55
 Employees 63
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -73
 Cash Flow (TTM) (Millions $) -51
 Capital Exp. (TTM) (Millions $) 2

Business Description


Omega Therapeutics Inc is a biotechnology company focused on developing therapies that target the human genome to treat various diseases. The company utilizes a novel approach called epigenomic programming, which involves modifying the gene expression patterns in cells to restore normal cellular function. Omega Therapeutics' therapies have the potential to address a wide range of diseases, including genetic disorders, cancer, and autoimmune conditions. The company aims to revolutionize the field of gene therapy and improve patient outcomes by targeting the underlying cause of diseases at the genetic level.


   Company Address: 140 First StreetSuite 501 Cambridge 2141 MA
   Company Phone Number: 949-4360   Stock Exchange / Ticker: NASDAQ OMGA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CRBU   -2.41%    
DNA   -0.93%    
FDMT        0.07% 
IMCR        1.01% 
RGNX   -7.14%    
RLAY        1.81% 
• View Complete Report
   



Clinical Study

Omega Therapeutics Unveils Breakthrough Epigenomic Medicine OTX-2002 in Nature Communications,

Published Tue, Sep 17 2024 11:00 AM UTC

Omega Therapeutics Announces Landmark Publication of Preclinical OTX-2002 Data in Nature Communications CAMBRIDGE, Mass. Sept. 17, 2024 Omega Therapeutics, Inc. (Nasdaq: OMGA), a leading clinical-stage biotechnology firm, has unveiled promising preclinical data on its novel epigenomic controller, OTX-2002, in the prestigious journal Nature Communications . This breakthr...
Management Changes

Omega Therapeutics Appoints Dr. Jennifer Nelson as Senior Vice President of Research, Bolstering Epigenomic Medicine Innovations,

Published Wed, Aug 14 2024 11:00 AM UTC

Omega Therapeutics Appoints Jennifer Nelson, Ph.D., as Senior Vice President of Research
CAMBRIDGE, Mass., Aug. 14, 2024 – Omega Therapeutics, a leading biotechnology company focused on the development of programmable epigenomic mRNA medicines, announced today the appointment of Jennifer Nelson, Ph.D., as Senior Vice President of Research. Dr. Nelson brings with her ov...
Product Service News

Omega Therapeutics Unveils New Preclinical Data, Showcases Promising Epigenomic Controllers in Functional Gene Expression Upregulation

Published Wed, May 8 2024 11:00 AM UTC

Encouraging Outcomes from the Ground-breaking Epigenomic Alteration ResearchOmega Therapeutics is a clinical-stage biotech outfit who has made its defining essence by leveraging the body s epigenomic control mechanisms to develop pioneering therapeutics. The firm recently presented compelling new preclinical data which conspicuously demonstrates durable and tunable bidirecti...
Clinical Study

Omega Therapeutics Presents Promising Findings on Epigenomic Control at AACR 2024, Paving the Way for Innovative Cancer Treatments

Published Tue, Apr 9 2024 11:01 AM UTC

Reprogramming Cancer: Omega Therapeutics Unveils Promising Preclinical Data at AACR 2024CAMBRIDGE, Mass., April 09, 2024 Omega Therapeutics, a groundbreaking clinical-stage biotechnology company specializing in programmable epigenomic mRNA medicines, wowed the scientific community at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego. Thei...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.97
Price to Sales (Expected) -
Price to Book 0.68
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.26
Working Capital Ratio 1.61
Leverage Ratio (MRQ) 12.23
Total Debt to Equity 1.35
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.33 $
Revenues (TTM) 0.15 $
Cash Flow (TTM) -
Cash 0.55 $
Book Value 0.21 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 128,476
Net Income per Employee (TTM) -1,160,190
Receivable Turnover Ratio (TTM) 3.83
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.12

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -628.64 %
Net Margin (MRQ) -629.56 %
Net Cash Flow Margin (MRQ) -592.46 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.